Table 4—

Vital signs for the placebo/epoprostenol and bosentan/epoprostenol groups at baseline and week 16 (safety population)

Vital signsPlacebo/epoprostenolBosentan/epoprostenol
BaselineEnd of treatmentAbsolute changeBaselineEnd of treatmentAbsolute change
Heart rate bpm85.2±4.591.8±3.36.6±3.683.8±2.183.3±1.8−0.5±3.0
Systolic BP mmHg120.4±4.8110.5±4.9−9.8±3.3110.2±2.7106.3±2.6−3.9±3.1
Diastolic BP mmHg75.9±4.670.0±3.3−5.9±2.871.9±2.365.9±2.3−6.0±2.7
  • Data are presented as mean±sem

  • BP: blood pressure

  • bpm: beats per minute

  • n=11 (placebo/epoprostenol) and 22 (bosentan/epoprostenol)